- DOI:
-
https://doi.org/10.57187/5215
Clinical reasoning: Case report
Vol. 156 No. 9 (2026)
An unusual cause of a necrotic bullous skin lesion: a case report
-
Cite this as:
-
Swiss Med Wkly. 2026;156:5215
-
Published
-
25.09.2026
Summary
BACKGROUND: Tularaemia is a zoonotic infection uncommon in Switzerland, but its incidence is increasing. Thus, tularaemia should also be considered in returning travellers with compatible exposure history. We report a case of ulceroglandular tularaemia presenting with a necrotic bullous skin lesion.
CASE PRESENTATION: A man in his 30s presented with a necrotic bullous lesion on the right palm, accompanied by ipsilateral axillary and supraclavicular lymphadenopathy. Eleven days prior, during a stay in Canada, he developed an itchy skin lesion and reported direct contact with a hare carcass five days before symptom onset. He initially received antibiotic therapy with a cephalosporin, which did not result in clinical improvement. A swab obtained from the lesion tested positive for Francisella tularensis subsp. tularensis by polymerase chain reaction (PCR), and serology confirmed the result.
TREATMENT AND OUTCOME: Antibiotic therapy was initially switched to doxycycline (100 mg twice daily), but discontinued after 6 days because of a sore throat suggestive of oesophageal irritation. Ciprofloxacin (500 mg twice daily) was subsequently administered for 10 days, during which the lesion, lymphadenopathy and general symptoms resolved rapidly.
This case highlights the importance of thorough exposure history and the early consideration of tularaemia in patients with necrotic skin lesions and regional lymphadenopathy, particularly when there is no response to standard antibiotic therapy. Early diagnosis allows for appropriate antimicrobial treatment and favourable outcomes.
References
- 1. Antonello RM, Giacomelli A, Riccardi N. Tularemia for clinicians: An up-to-date review on epidemiology, diagnosis, prevention and treatment. European Journal of Internal Medicine. 2025 May;135:25-32. doi:10.1016/j.ejim.2025.03.013
- 2. Maurin M, Pondérand L, Hennebique A, Pelloux I, Boisset S, Caspar Y. Tularemia treatment: experimental and clinical data. Frontiers in Microbiology. 2024 Jan 17;14:1348323. doi:10.3389/fmicb.2023.1348323
- 3. Maurin M, Gyuranecz M. Tularaemia: clinical aspects in Europe. The Lancet Infectious Diseases. 2016 Jan;16(1):113-124. doi:10.1016/S1473-3099(15)00355-2
- 4. Bundesamt für Gesundheit (BAG). Infectious diseases: overview [Internet]. Bern: BAG; 2026. Available from: https://www.idd.bag.admin.ch/diseases/overview
- 5. Buettcher M, Egli A, Albini S, Altpeter E, Labutin A, Guidi V, et al. Tularemia on the rise in Switzerland? A one health approach is needed!. Infection. 2024 Jun;52(3):1165-1169. doi:10.1007/s15010-024-02218-9
- 6. Schütz SD, Liechti N, Altpeter E, Labutin A, Wütrich T, Schmidt KM, et al. Phylogeography of Francisella tularensis subspecies holarctica and epidemiology of tularemia in Switzerland. Frontiers in Microbiology. 2023 Apr 11;14:1151049. doi:10.3389/fmicb.2023.1151049
- 7. Frischknecht M, Meier A, Mani B, Joerg L, Kim OC, Boggian K, et al. Tularemia: an experience of 13 cases including a rare myocarditis in a referral center in Eastern Switzerland (Central Europe) and a review of the literature. Infection. 2019 Oct;47(5):683-695. doi:10.1007/s15010-019-01269-7
- 8. Maurin M, Mersali NF, Raoult D. Bactericidal Activities of Antibiotics against Intracellular Francisella tularensis. Antimicrobial Agents and Chemotherapy. 2000 Dec;44(12):3428-3431. doi:10.1128/AAC.44.12.3428-3431.2000
- 9. Centers for Disease Control and Prevention (CDC). Tularemia transmitted by insect bites—Wyoming, 2001–2003. MMWR Morb Mortal Wkly Rep. 2005;54(7):170–173.
- 10. Nelson CA, Meaney-Delman D, Fleck-Derderian S, Winberg J, Mead PS. Tularemia Antimicrobial Treatment and Prophylaxis: CDC Recommendations for Naturally Acquired Infections and Bioterrorism Response — United States, 2025. MMWR. Recommendations and Reports. 2025 Oct 2;74(2):1-33. doi:10.15585/mmwr.rr7402a1